Table 2.
Summary of pooled data from included research papers have been reported in the literature (n = 218).
| Age | Median age - 29.23 years |
|---|---|
| Gender (n) % | Male – 201 (92.2%) |
| Female – 17 (7.8%) | |
| Type of COVID-19 vaccine (n) % | Pfizer-BioNTech (BNT162b2) – 158 (72.4%) |
| Moderna COVID-19 Vaccine (mRNA-1273) - 52 (23.8%) | |
| Janssen (Johnson & Johnson) (Ad26.COV2. S) – 4 (1.8%) | |
| Oxford, AstraZeneca COVID-19 vaccine ChAdOx1 nCoV-19 – 2 (0.9%) | |
| Sinovac COVID-19 vaccine in activated – 1 (0.4%) | |
| rAd26 and rAd5 (Sputnik V vaccine) – 1 (0.4%) | |
| Dose (n) % | First dose – 28 (12.8%) |
| Second dose – 179 (82.1%) | |
| Third dose – 11 (5.1%) | |
| Days to symptom onset | Median 3.57 days |
| Symptoms (n) % | Chest pain - 216 (99.1%) |
| Fever – 69 (31.6%) | |
| Myalgia/body aches – 80 (36.6%) | |
| Shortness of breath – 19 (8.7%) | |
| Troponin level (n) % | Elevated – 215 (98.6%) |
| Not elevated – 2 (0.9%) | |
| Unknown – 1 (0.4%) | |
| LVEF (n) % | LVEF >50% - 169 (77.5%) |
| LVEF <50% - 47 (21.5%) | |
| Unknown – 2 (0.9%) | |
| Electrocardiogram (ECG) (n) % | Abnormal – 193 (88.5%) |
| Normal – 25 (11.5%) | |
| Length of hospital stay (days) | Median 5.8 days in 182 patients |
| Unknown in 36 patients | |
| Outcome (n) % | Recovered – 202 (92.6%) |
| Under follow-up – 7 (3.2%) | |
| Unknown – 7 (2.7%) | |
| Died – 3 (1.4%) |